Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

ABSTRACT:

Background

A prophylactic HIV-1 vaccine is a global health priority.

Objective

To assess a novel vaccine platform as a prophylactic HIV-1 regimen.

Design

Randomized, double-blind, placebo-controlled trial. Both participants and study personnel were blinded to treatment allocation. (ClinicalTrials.gov: NCT01215149).

Setting

United States, East Africa, and South Africa.

Patients

Healthy adults without HIV infection.

Intervention

2 HIV-1 vaccines (adenovirus serotype 26 with an HIV-1 envelope A insert [Ad26.EnvA] and adenovirus serotype 35 with an HIV-1 envelope A insert [Ad35.Env], both administered at a dose of 5 × 1010 viral particles) in homologous and heterologous combinations.

Measurements

Safety and immunogenicity and the effect of base

SUBMITTER: Baden LR 

PROVIDER: S-EPMC5034222 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature